Trial Profile
Effects of the dipeptidyl peptidase-4 (DPP-4) inhibitor linagliptin on left ventricular myocardial DYsfunction in patients with type 2 DiAbetes mellitus and concentric left ventricular geometry
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 29 Dec 2021
Price :
$35
*
At a glance
- Drugs Linagliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms DYDA2
- 29 Nov 2021 Results published in the European Clinical Trials Database Trial Registry.
- 22 Jul 2019 Status changed from active, no longer recruiting to completed.
- 08 Aug 2018 Planned End Date changed from 1 May 2018 to 1 Apr 2019.